GLP-1 Cancer Research Expands Beyond Colon

UC San Diego researchers previously reported that colon cancer patients on GLP-1 drugs like Ozempic and Wegovy died at less than half the rate of non-users — 15.5% versus 37.1% over five years. That study, led by Dr. Raphael Cuomo, covered more than 6,800 patients.

Now the research is expanding beyond a single cancer type. A new analysis from Memorial Sloan Kettering suggests the implications are much broader.

Memorial Sloan Kettering Puts a Number on It

In a paper published in March 2026 in JAMA Network, Memorial Sloan Kettering breast oncologist Dr. Sherry Shen and her co-authors quantified the scope of obesity-related cancers.

Overweight and obesity account for approximately 10% of all new cancer diagnoses in the United States annually. For certain cancers — endometrial and hepatobiliary tumors — obesity is implicated in up to 50% of cases.

13 Cancer Types on the Radar

Dr. Shen identified at least 13 cancer types linked to obesity. The list includes post-menopausal breast cancer, colon cancer, gastric cancer, prostate cancer, endometrial cancer, and liver/bile duct cancers.

"These medications look to be promising in potentially reducing the number of people who are diagnosed with these obesity-related cancers," Dr. Shen said in a statement from Memorial Sloan Kettering Cancer Center.

Her earlier work — published in August 2025 — found GLP-1 drugs helped breast cancer patients manage weight gain during treatment. Weight gain is a documented side effect of breast cancer therapy that worsens cardiovascular outcomes and can worsen overall prognosis.

Why These Drugs Might Work Against Cancer

GLP-1 receptors aren't limited to the gut or pancreas. These drugs influence brain regions tied to reward, reshape metabolic pathways linked to inflammation, and alter how the body handles energy at a systemic level.

Obesity and metabolic dysfunction make cancers more aggressive. Tumors thrive in environments with high insulin, chronic inflammation, and disrupted energy regulation — conditions that GLP-1 drugs appear to correct.

The UC San Diego team noted the benefit was strongest in patients with BMI over 35, pointing directly at this metabolic mechanism. The drugs may be offsetting the inflammatory and metabolic conditions that make cancer harder to treat and easier to spread.

Beyond Weight Loss

Most media coverage frames this as an "Ozempic weight loss drug has surprising cancer benefit" story. Researchers are investigating whether GLP-1 drugs have a direct anti-cancer mechanism independent of weight loss. The UC San Diego data held up even after controlling for age, BMI, cancer severity, and other health conditions.

The JAMA Network paper from MSK frames this as a public health intervention question — not just a treatment question. If obesity drives 10% of all U.S. cancer diagnoses, and these drugs reduce obesity and its metabolic consequences, the preventive implications become significant.

What's Still Missing: Clinical Trials

Dr. Cuomo's team called for clinical trials after publishing the colon cancer data. Dr. Shen echoes that caution — she told MSK that "these are early days" and "much research" remains.

The existing data is observational. Researchers looked at what happened to patients already on these drugs for other reasons. No randomized controlled trial has yet tested GLP-1 drugs as a direct cancer intervention.

Until those trials run, no oncologist should prescribe Ozempic specifically to treat cancer.

Access and the Bigger Problem

Dr. Shen raised a projection worth considering. By 2030, severe obesity is projected to become the dominant weight category in many U.S. states.

If that projection holds, and the cancer-obesity link is as strong as the data suggests, the United States could face a wave of cancer diagnoses driven by metabolic disease.

GLP-1 drugs are expensive and largely unaffordable without insurance for millions of Americans. Supply constraints persist. The people most at risk from obesity-linked cancers are often least likely to access these medications.

The question facing policymakers is whether these drugs can reach the people who need them before obesity projections translate into a surge of cancer diagnoses.